Verastem, Inc. VSTM
Verastem, Inc. (Nasdaq: VSTM) is an oncology drug developer. Its lead program, AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib), is in Phase 2 for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) after prior systemic therapy. Its next catalyst on record is VS-7375 (TARGET-D 301): Company plans to open TARGET-D 301 Phase 3 trial in first-line mPDAC by year-end 2026 following FDA alignment on study design. (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VS-7375 (TARGET-D 301) — Company plans to open TARGET-D 301 Phase 3 trial in first-line mPDAC by year-end 2026 following FDA alignment on study design. (2026). 14 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| AVMAPKI FAKZYNJA CO-PACK (avutometinib + defactinib) | KRAS-mutated recurrent LGSOC (FDA accelerated approval 2025-05-08; marketed in US; Phase 3 RAMP 301 confirmatory/expansion fully enrolled) | small molecule | Approved |
| VS-7375 (oral KRAS G12D ON/OFF inhibitor; licensed from GenFleet) | KRAS G12D-mutated PDAC, NSCLC, CRC (TARGET-D 101 Phase 1/2; three Phase 2 registration-directed trials TARGET-D 201/202/203 dosed) | small molecule | Phase 2 |
| Avutometinib + defactinib + gemcitabine/nab-paclitaxel (RAMP 205) | first-line metastatic pancreatic cancer (Phase 1b/2a; RP2D cohort of 29, 52% cORR at June 2026 cutoff) | small molecule | Phase 2 |
| Avutometinib + defactinib + sotorasib (RAMP 203) | KRAS G12C NSCLC (discontinued December 2025) | small molecule | Phase 1 |
| Undisclosed discovery assets (GenFleet collaboration) | RAS/MAPK pathway-driven cancers | small molecule | Pre-clinical |
Recent results and decisions
- Jan 1, 2027n/a Michael P. Bailey appointed President and CEO of Verastem effective January 1, 2027; Daniel Paterson to retire and remain as advisor and Board member.
Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1, 2027. The CEO transition follows the planned retirement of Daniel Paterson.
Filing - Oct 14, 2026positive VS-7375 600 mg monotherapy in 2L+ KRAS G12D NSCLC showed 43% confirmed ORR (10/23), 72% 6-month landmark PFS, 17/23 on treatment (cutoff Oct 7, 2026).
VS - 7375 Demonstrates Confirmed Responses at 600 mg in 2L+ NSCLC 43% c ORR (10/23) 2L+ NSCLC, including prior taxane treated
Filing - Oct 14, 2026positive VS-7375 600 mg with first-line SoC triplet in KRAS G12D NSCLC showed 75% ORR (6/8), 6/8 remain on treatment.
75% ORR* (6/8) in 1L NSCLC combined with SoC mITT = 8 patients
Filing
17 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.